SCHEMBL4756464

SCHEMBL4756464

OCCc1nc2ccccc2c2[nH]cnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.54
TERT O14746 2/20 0.36
POLB P06746 2/20 0.36
RAD52 P43351 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MITF O75030 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TTR P02766 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PDPK1 O15530 1/20 0.36
CA12 O43570 1/20 0.36
PARP1 P09874 1/20 0.36
ALOX15 P16050 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA9 Q16790 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10743106 0.85 JAK2 (0.46) JAK2POLBALDH1A1LMNAGAA
SCHEMBL18986860 0.83 JAK2 (0.49) JAK2KDM4EALDH1A1GAAPARP1
Propionic Acid SCHEMBL8573908 0.79 JAK2 (0.47) JAK2POLBKDM4EALDH1A1LMNA
SCHEMBL6701755 0.79 JAK2 (0.43) JAK2POLBRAD52KDM4EGLA
Alcohol SCHEMBL5925469 0.79 JAK2 (0.43) JAK2POLBRAD52KDM4EALDH1A1
SCHEMBL5032885 0.78 ELANE (0.43) JAK2POLBLMNAKMT2APDPK1
SCHEMBL9603146 0.77 SLC6A4 (0.44) JAK2
SCHEMBL311169 0.76 JAK2 (0.41) JAK2POLBRAD52KDM4EALDH1A1
SCHEMBL17670057 0.76 JAK2 (0.40) JAK2POLBRAD52KDM4EALDH1A1
Hydrochloric Acid SCHEMBL9037659 0.75 JAK2 (0.41) JAK2POLBRAD52KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021116420-A1 USE OF TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF LEPTOSPIROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-06-17 WO disclosed
EP-3294295-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2018-03-21 EP disclosed
EP-3097416-A2 METHODS FOR TESTING T CELL PRIMING EFFICACY IN A SUBJECT INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-11-30 EP disclosed
WO-2016180945-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-11-17 WO disclosed
WO-2016180852-A1 METHODS FOR PREPARING ANTIGEN-SPECIFIC T CELLS FROM AN UMBILICAL CORD BLOOD SAMPLE INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-11-17 WO disclosed
EP-3024476-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-06-01 EP disclosed
WO-2015110397-A2 METHODS FOR TESTING T CELL PRIMING EFFICACY IN A SUBJECT INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-07-30 WO disclosed
WO-2015011254-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-01-29 WO disclosed
WO-2008004992-A2 TRANSDERMAL FORMULATIONS CONTAINING HEPATITIS C VIRUS IMMUNOGENS AND AN ETHOXYLATED OIL TRIPEP AB (SE) 2008-01-10 WO disclosed
EP-1819364-A2 IMMUNOMODULATORY COMPOSITIONS, COMBINATIONS AND METHODS 3M Innovative Properties Company (US) 2007-08-22 EP disclosed
WO-2006063072-A2 IMMUNOMODULATORY COMPOSITIONS, COMBINATIONS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-06-15 WO disclosed
WO-2006029223-A2 METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2006-03-16 WO disclosed